We will discuss case study experiences involving collaboration in drug and biotech discovery and development, obstacles experienced in practice and methods used to overcome barriers, approaches used to data sharing including IP and contractual issues, practices in knowledge management and innovation success.
We will subsequently flush out the real problems and issues involved in current practices in translational medicine, identify the strengths and weaknesses in current approaches being used and explore new strategies that might be of use to address and achieve improved translational success.
The workshop will be facilitated by Frank Hollinger (Sphaera Pharma), Michael Liebman (Strategic Medicine) and Barry Hardy (Douglas Connect).
I am pleased to announce the program for the OpenTox USA 2015 meeting which will take place 10-12 Feburary at Johns Hopkins, Baltimore.
The goal of the meeting is to discuss and develop important components for driving 21st century approaches to safety assessment forward. We assume that collaboration driven by an open global platform and open standards will be a key success factor. Integrating heterogenous evidence supported by a common knowledge framework and ecosystem of tools and partners will enable practical application, judgements and decisions including industrial application and regulatory acceptance.
The program will involve conference sessions and associated hands-on workshops, poster session and knowledge cafes.
The main themes of the meeting are:
Data Science, facilitated by Barry Hardy (Douglas Connect) Adverse Outcome Pathways, facilitated by Stephen Edwards (US EPA) Exposure Modelling, facilitated by Tim Pastoor (Syngenta) Integrating Evidence and Analysis, Thomas Hartung (Johns Hopkins) Risk Assessment & Management Applications, Grace Patlewicz (Du Pont)
We are open for submission of abstracts for consideration for the program.